<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adjuvant and neoadjuvant therapy for cutaneous melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adjuvant and neoadjuvant therapy for cutaneous melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Adjuvant and neoadjuvant therapy for cutaneous melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Sosman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgical excision is the treatment of choice for most patients with locoregional cutaneous melanoma and is also curative in most cases. However, some patients will subsequently relapse with disseminated disease. Specific clinical features in the primary tumor and regional lymph nodes are associated with increased risk for disease recurrence.</p><p>Checkpoint inhibition immunotherapy and targeted therapies are important advances in the treatment of patients with cutaneous melanoma, in the metastatic setting; in the adjuvant setting for patients at high risk for recurrence following initial surgery; and in the neoadjuvant setting prior to definitive surgery. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Treatment-naive patients'</a>.)</p><p>The use of immunotherapy and targeted therapy as adjuvant and neoadjuvant treatment for cutaneous melanoma will be reviewed here. The initial surgical management of cutaneous melanoma and systemic treatment of patients with metastatic disease are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="headingAnchor" id="H157827371"><span class="h1">FACTORS THAT INFLUENCE THERAPY</span><span class="headingEndMark"> — </span>For patients with resectable cutaneous melanoma, various clinical factors influence both the decision to offer adjuvant or neoadjuvant therapy and the choice of agent. The factors include the risk of disease recurrence, stage at diagnosis, degree of lymph node involvement (microscopic versus macroscopic), <em>BRAF</em> mutation status, and patient characteristics such as age, comorbidities, and treatment preferences. While effective treatments are available, patients can also be encouraged to enroll in clinical trials.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of disease recurrence</strong> – The extent and characteristics of the primary tumor and regional lymph node involvement allow classification of patients into different categories of risk for disease recurrence. The eighth edition of the tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) incorporates the most important determinants of prognosis and is one factor used to select adjuvant or neoadjuvant therapy [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the primary tumor (T), increasing tumor thickness, the presence of ulceration (ie, the loss of the epidermal layer overlying the primary tumor), and increased mitotic rate [<a href="#rid3">3</a>] are all associated with an increased risk of relapse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of lymph node involvement is associated with a significant increase in risk of relapse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF </em></strong><strong>mutation status</strong> – Patients with high-risk node-positive microscopic disease that harbor a <em>BRAF</em> V600 mutation have the option of adjuvant therapy with either immunotherapy or targeted therapy (ie, BRAF plus MEK inhibitors). (See <a class="local">'BRAF-mutated tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient characteristics</strong> – Patient characteristics such as age, comorbidities (eg, active autoimmune disease), and treatment preferences will also influence the choice of therapy. Eligibility for immunotherapy and toxicities associated with targeted therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Defining immunotherapy eligibility'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H157827551"><span class="h1">LOW-RISK NODE-NEGATIVE DISEASE (STAGE I AND IIA)</span></p><p class="headingAnchor" id="H3080547567"><span class="h2">Surveillance</span><span class="headingEndMark"> — </span>Patients with low-risk node-negative melanoma present with AJCC eighth edition stage I or IIA disease  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>). They have a primary tumor with low-risk features (either ≤2 mm in thickness with or without ulceration or ≤4 mm in thickness without ulceration), but no lymph node involvement. Since these patients are at low risk for disease recurrence, surgery alone is usually curative and adjuvant therapy is not indicated  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>) [<a href="#rid4">4</a>]. Clinical trials are an alternative to surveillance, where available. (See  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma", section on 'Surveillance'</a>.)</p><p class="headingAnchor" id="H157827560"><span class="h1">HIGH-RISK NODE-NEGATIVE DISEASE (STAGE IIB AND IIC)</span><span class="headingEndMark"> — </span>Patients with high-risk node-negative melanoma present with AJCC eighth edition stage IIB and IIC disease  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>). They have a primary tumor that is thick and/or ulcerated (&gt;4 mm thick with or without ulceration, or &gt;2 to 4 mm thick with ulceration), but no lymph node involvement. Patients with stage IIB and IIC disease are at a similar or increased risk for recurrence and metastatic disease as a subset of those with stage III disease  (<a class="graphic graphic_figure graphicRef134094" href="/d/graphic/134094.html" rel="external">figure 1</a>). </p><p>For patients with resected high-risk node-negative (stage IIB and IIC) melanoma, we suggest one year of adjuvant immunotherapy with either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) rather than surveillance  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>). However, surveillance or enrollment in a clinical trial are reasonable alternatives, particularly those with stage IIB disease who have a lower risk of disease recurrence, pending longer follow-up data for overall survival (OS) with adjuvant immunotherapy. Patients with stage IIB disease have a lower risk of disease recurrence, so surveillance avoids the potential risks of long-term immunotherapy-related adverse events and preserves immunotherapy as a treatment option if their disease recurs. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="headingAnchor" id="H1541244557"><span class="h2">Adjuvant pembrolizumab</span><span class="headingEndMark"> — </span>In patients with resected, high-risk node-negative (stage IIB and IIC) melanoma, one year of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) improved recurrence-free survival (RFS) over placebo and was well tolerated in a phase III trial [<a href="#rid5">5-7</a>]. </p><p>Patients with high-risk node-negative disease are at similar or increased risk for recurrence and metastatic disease as other patients with node-positive disease  (<a class="graphic graphic_figure graphicRef134094" href="/d/graphic/134094.html" rel="external">figure 1</a>). However, they were excluded from initial phase III clinical trials evaluating adjuvant immunotherapy and targeted agents in resected melanoma [<a href="#rid8">8-11</a>]. Subsequently, an international, double-blind, placebo-controlled phase III trial (KEYNOTE-716) was conducted to evaluate the use of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) in 976 patients with completed resected cutaneous stage IIB or IIC melanoma [<a href="#rid5">5,7</a>] including adults and children older than 12 years of age. In this study, patients were randomly assigned to either adjuvant pembrolizumab at a dose of 200 mg intravenously every three weeks (or 2 mg/kg every three weeks for pediatric patients) for up to one year or placebo.</p><p>At median follow-up of 27 months, for all patients, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved RFS over placebo (two-year RFS 81 versus 73 percent, HR 0.64, 95% CI 0.50-0.84) [<a href="#rid7">7</a>]. In a subgroup analysis, adjuvant pembrolizumab also improved RFS for patients with stage IIB disease (T3b, hazard ratio [HR] 0.57, 95% CI 0.36-0.89; T4a, HR 0.48, 95% CI 0.26-0.90) and trended towards improved RFS for stage IIC disease (T4b, HR 0.76, 95% CI 0.51-1.13). Adjuvant pembrolizumab also improved distant metastasis-free survival (DMFS) over placebo (two-year DMFS 88 versus 82 percent, HR 0.64, 95% CI 0.47-0.88), with a consistent benefit across all tumor stages. Grade ≥3 toxicity rates were higher for pembrolizumab compared with placebo (17 versus 5 percent). The most common immune-mediated endocrine adverse events were hypothyroidism (17 versus 4 percent), hypophysitis (2 versus 0 percent), adrenal insufficiency (3 versus 0 percent), hyperthyroidism (2 versus &lt;1 percent), and type I diabetes mellitus (&lt;1 versus 0 percent)</p><p>Based on these data, the US Food and Drug Administration (FDA) approved adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for adult patients with stage IIB and IIC melanoma following complete resection [<a href="#rid12">12</a>]. The use of adjuvant pembrolizumab in pediatric patients is discussed below. (See <a class="local">'Pediatric and adolescent patients'</a> below.)</p><p class="headingAnchor" id="H2481104295"><span class="h2">Adjuvant nivolumab</span><span class="headingEndMark"> — </span>In patients with high-risk node-negative (stage IIB and IIC) melanoma, one year of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved RFS over placebo and was well tolerated in a phase III trial [<a href="#rid13">13</a>]. </p><p>Adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was evaluated in a randomized, open-label, placebo-controlled phase III trial (CheckMate-76K) of 760 patients with completely resected stage IIB and IIC melanoma [<a href="#rid13">13</a>]. In preliminary results, at median follow-up of approximately 16 months, one year of adjuvant nivolumab improved RFS (one-year RFS 89 versus 79 percent; HR 0.42, 95% CI 0.30-0.59) and DMFS (one-year DMFS 92 versus 87 percent; HR 0.47, 95% CI 0.30-0.72) over placebo. RFS benefit for adjuvant nivolumab was also seen among the subgroups with stage IIB and IIC disease. Grade ≥3 treatment-related toxicity was higher for nivolumab versus placebo (10 versus 2 percent). </p><p>Based on these data, the FDA approved adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> for adult patients with stage IIB and IIC melanoma following complete resection [<a href="#rid14">14</a>]. The use of adjuvant nivolumab in pediatric patients is discussed below. (See <a class="local">'Pediatric and adolescent patients'</a> below.)</p><p class="headingAnchor" id="H2612767523"><span class="h1">LOW-RISK NODE-POSITIVE DISEASE (STAGE IIIA)</span><span class="headingEndMark"> — </span>For patients with resected, low-risk node-positive (AJCC eighth edition stage IIIA) melanoma  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>), the approach to adjuvant therapy is as follows  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest surveillance rather than systemic therapy in patients with resected stage IIIA disease  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>) who have a non-ulcerated primary tumor ≤2 mm in thickness and sentinel lymph nodes containing &lt;1 mm of tumor. Data suggest that these patients with small volume disease have a lower risk of disease recurrence (estimated at less than 20 percent [<a href="#rid4">4,15,16</a>]) and a five-year recurrence-free survival (RFS) of over 90 percent [<a href="#rid17">17,18</a>]. Clinical trials of adjuvant therapy have not typically included these patients due to the low risk of recurrence. Patients who choose surveillance instead of systemic therapy can avoid treatment-related toxicity, and its use can be reserved in the event of recurrent or metastatic disease. (See  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma", section on 'Surveillance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all other patients with resected stage IIIA melanoma  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>), we treat with one year of adjuvant systemic therapy, based upon the <em>BRAF</em> mutation status of the tumor  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with <em>BRAF</em> wild-type tumors, we offer a single-agent programmed cell death-1 (PD-1) inhibitor (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>)). The choice of therapy is discussed below. (See <a class="local">'BRAF wild-type tumors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with <em>BRAF</em> mutant tumors, we offer either a single-agent PD-1 inhibitor (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>)) or targeted therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>. The choice of therapy is discussed below. (See <a class="local">'BRAF-mutated tumors'</a> below.)</p><p></p><p>The approach to adjuvant and neoadjuvant therapy for more advanced, higher-risk stage III tumors is discussed separately. (See <a class="local">'High-risk node-positive disease (stage IIIB, IIIC, IIID)'</a> below.)</p><p class="headingAnchor" id="H756639206"><span class="h1">HIGH-RISK NODE-POSITIVE DISEASE (STAGE IIIB, IIIC, IIID)</span><span class="headingEndMark"> — </span>Patients with high-risk node-positive disease (AJCC eighth edition stage IIIB, IIIC, and IIID disease  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) are at significant risk for disease recurrence [<a href="#rid4">4</a>]. Treatment options for these patients include systemic therapy (immune checkpoint inhibitors or targeted therapy) and surgery. Multidisciplinary evaluation is necessary to determine the appropriate sequencing of this treatments, with input from medical oncology, surgical oncology, and radiation oncology.</p><p class="headingAnchor" id="H2222789626"><span class="h2">Macroscopic disease</span><span class="headingEndMark"> — </span>For patients with high-risk node-positive (AJCC eight edition stage IIIB, IIIC, and IIID  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) melanoma and macroscopic disease that is resectable, we suggest initial treatment with neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than primary surgery, based on improved event-free survival (EFS) in a randomized phase II trial (SWOG S1801) [<a href="#rid19">19</a>]. Macroscopic disease is defined as clinically detected lymph nodes on radiographic imaging or physical exam, or visible in-transit or satellite metastases that are subsequently confirmed on pathology (eg, fine needle aspiration [FNA], incisional, or excisional biopsy). For patients who select neoadjuvant pembrolizumab, specific management details are discussed below. (See <a class="local">'Neoadjuvant pembrolizumab'</a> below.)</p><p>Alternative options for neoadjuvant therapy in this population include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, based on data from phase I and II trials, or enrollment in clinical trials investigating other neoadjuvant regimens, where available. (See <a class="local">'Neoadjuvant nivolumab plus ipilimumab'</a> below and <a class="local">'Investigational approaches'</a> below.) </p><p class="headingAnchor" id="H492370263"><span class="h3">Pathologic responses to neoadjuvant immunotherapy</span><span class="headingEndMark"> — </span>Patients treated with neoadjuvant immunotherapy have varying pathologic responses at surgical resection, which are defined as follows [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete pathologic response (pCR)</strong> – No viable tumor cells</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major pathologic response (mPR)</strong> – ≤10 percent viable tumors cells (ie, pathologic complete response [pCR] or near pCR) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic partial response (pPR)</strong> – Between 10 and 50 percent viable tumor cells </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic nonresponse (pNR)</strong> – Greater than 50 percent viable tumor cells</p><p></p><p class="headingAnchor" id="H1126662593"><span class="h3">Neoadjuvant pembrolizumab</span><span class="headingEndMark"> — </span>Neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is effective in patients with high-risk node-positive macroscopic disease. This approach is based on a randomized phase II trial (SWOG S1801) where one year of perioperative (neoadjuvant and adjuvant) pembrolizumab improved EFS over primary resection plus adjuvant pembrolizumab and was well tolerated [<a href="#rid19">19</a>]. This study established the concept that neoadjuvant immunotherapy is more effective than primary surgery followed by adjuvant immunotherapy.</p><p>Neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is administered at 200 mg intravenously (IV) every three weeks over three cycles, followed by surgery (therapeutic lymph node dissection). Patients who complete neoadjuvant pembrolizumab and surgery are then treated with an additional fifteen cycles of adjuvant pembrolizumab to complete up to one year of therapy. Although data are limited, patients with a pNR and <em>BRAF</em> mutant disease may alternatively switch to one year of adjuvant targeted therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, since tumors with a pNR are likely resistant to immunotherapy.</p><p>Initial phase I and II trials of neoadjuvant PD-1 inhibitors (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) demonstrated mPR rates of up to 30 percent in patients with cutaneous melanoma [<a href="#rid20">20-23</a>]. Based on these data, neoadjuvant pembrolizumab was evaluated in an open-label, randomized phase II trial (SWOG S1801) of 313 patients with resectable macroscopic stage IIIB-IV cutaneous, acral, and mucosal melanoma without brain metastases [<a href="#rid19">19</a>]. In this study, patients were randomly assigned to either neoadjuvant immunotherapy (three cycles of preoperative pembrolizumab at 200 mg administered IV every three weeks followed by surgery and fifteen cycles of adjuvant pembrolizumab) or adjuvant immunotherapy (primary surgery followed by eighteen cycles of adjuvant pembrolizumab).</p><p>At median follow-up of 15 months, neoadjuvant immunotherapy improved EFS compared with adjuvant therapy in the entire study population (two-year EFS 72 versus 49 percent, HR 0.58, 95% CI 0.39-0.87) [<a href="#rid19">19</a>]. An EFS benefit for neoadjuvant immunotherapy was also seen across multiple clinical subgroups including stage (stage IIIB, HR 0.91; stage IIIC, hazard ratio [HR] 0.4; stage IIID/IV, HR 0.45), lactate dehydrogenase (LDH) levels, and <em>BRAF</em> status (<em>BRAF</em>-mutant; HR 0.44, 95% CI 0.21-0.91; <em>BRAF</em> wild-type, HR 0.72, 95% CI 0.38-1.35). Overall survival (OS) data were immature (HR 0.63, 95% CI 0.32-1.24).</p><p>Among 142 evaluable patients treated with neoadjuvant therapy, complete and partial radiographic response rates were 6 and 41 percent, respectively. Although a similar proportion of patients were able to proceed to surgery in each treatment arm, tumor-related events (disease progression or recurrence) occurred less frequently with neoadjuvant therapy versus adjuvant therapy (20 versus 40 percent). The pCR rate for neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was 21 percent at initial institutional evaluation. Neoadjuvant pembrolizumab did not significantly increase toxicity in the perioperative period compared with adjuvant therapy, as grade ≥3 toxicity rates were similar during the surgical (12 versus 5 percent) and adjuvant periods (9 versus 16 percent).</p><p>Neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> also has activity in <em>BRAF</em> mutant disease (mPR rates of approximately 40 percent in one randomized trial [NEOTrio] [<a href="#rid21">21</a>]); and locally advanced desmoplastic melanoma, which is particularly responsive to immunotherapy (pCR rates of approximately 55 percent in one phase II study [SWOG 1512] [<a href="#rid24">24</a>]). (See  <a class="medical medical_review" href="/d/html/7614.html" rel="external">"Radiation therapy in the management of melanoma", section on 'Desmoplastic melanoma'</a> and  <a class="medical medical_review" href="/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma", section on 'Desmoplastic melanoma'</a>.)</p><p>Longer term follow-up suggests response to neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is an important prognostic variable. In a phase I trial of 30 patients, those with major or complete pathologic response following a single dose of neoadjuvant pembrolizumab had higher five-year OS (100 versus 73 percent) and lower recurrence rates (25 versus 36 percent) when compared with those who had residual tumor at the time of surgery [<a href="#rid25">25</a>]. Limitations of this study include its small size and use of a single dose of pembrolizumab.</p><p class="headingAnchor" id="H1204212267"><span class="h3">Neoadjuvant nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>Neoadjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is another option for patients with high-risk macroscopic node-positive disease, extrapolating from phase I and II trial data [<a href="#rid26">26-30</a>]. In these studies, neoadjuvant nivolumab plus ipilimumab was well tolerated, reduced surgical morbidity, and demonstrated mPR rates between 70 to 80 percent that were durable. (See <a class="local">'Pathologic responses to neoadjuvant immunotherapy'</a> above and <a class="local">'Limited nodal resection after neoadjuvant immunotherapy'</a> below.)</p><p>Neoadjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg) plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (1 mg/kg) is administered IV every three weeks for up to two cycles total, followed by surgery (therapeutic lymph node dissection). Patients who complete neoadjuvant nivolumab plus ipilimumab as well as surgery can receive adjuvant nivolumab to complete up to one year of systemic therapy. However, for patients with an mPR, the approach to adjuvant therapy is evolving, as data from a phase II trial (PRADO) suggest that a full year of adjuvant therapy may not be required [<a href="#rid30">30</a>]. (See <a class="local">'Limited nodal resection after neoadjuvant immunotherapy'</a> below.)</p><p class="headingAnchor" id="H536090400"><span class="h3">Investigational approaches</span></p><p class="headingAnchor" id="H80258054"><span class="h4">Limited nodal resection after neoadjuvant immunotherapy</span><span class="headingEndMark"> — </span>For patients treated with neoadjuvant immunotherapy, data suggest that limited initial resection of a select involved lymph node (rather than a therapeutic lymph node dissection [TLND]) could be used to guide further surgery and adjuvant systemic therapy.</p><p>In an open-label phase II trial (PRADO), 99 patients with stage IIIB or IIIC melanoma and an index lymph node (ILN) that was measurable on computed tomography imaging and able to be marked with a fiducial were treated neoadjuvantly with the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg) and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (1 mg/kg) every three weeks for up to two doses, followed by resection of the marked ILN [<a href="#rid30">30</a>]. This neoadjuvant treatment strategy had previously been established by a randomized phase II trial (OpACIN-neo) [<a href="#rid26">26,31</a>]. Patients were subsequently treated using a personalized response-driven approach based on the pathologic response rate of the ILN. (See <a class="local">'Pathologic responses to neoadjuvant immunotherapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with an mPR (which included those with a pCR) did not receive further surgery (eg, TLND) or systemic therapy and were observed; those with a pPR received TLND followed by observation; those with a pNR received TLND followed by adjuvant systemic therapy (either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or the combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> in patients with a <em>BRAF </em>V600-mutated tumor).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the entire study population, pathologic responses from combination immunotherapy were seen in 71 patients (72 percent), including 60 patients with either a pCR or near pCR (61 percent) and 11 patients with a pPR (11 percent); pNR was seen in 20 patients (21 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The overall radiologic response rate was 45 percent and accurately identified seven patients (7 percent) who developed distant metastatic disease prior to ILN resection, influencing their subsequent treatment strategies; however, imaging assessment generally underestimated the degree of pathologic responses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The grade ≥3 immune-mediated adverse event rate was 30 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using neoadjuvant immunotherapy, TLND was omitted in 59 of 99 patients (60 percent). Additionally, compared with patients treated with TLND, those who received ILN surgery alone reported reduced rates of surgical adverse events (84 versus 46 percent) and improved quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At median follow-up of 28 months, in all patients, two-year recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were 85 and 89 percent, respectively. Patients with mPR also demonstrated excellent two-year RFS and DMFS (93 and 98 percent). However, patients with a pPR, who were observed after TLND, may also benefit from adjuvant therapy, as these patients had lower two-year RFS and DMFS (64 percent each) than those with pNR, who received adjuvant therapy after TLND (71 and 76 percent) [<a href="#rid30">30</a>].</p><p></p><p>Data from the PRADO trial suggest that after neoadjuvant immunotherapy, a limited initial resection of one involved lymph node could be used to determine further surgery and adjuvant therapy. For some patients, this approach could potentially avoid the surgical morbidity associated with more extensive surgery (ie, TLND). Treatment could be selected based on the pathologic response of the resected lymph node. Patients with an mPR may not require further surgery and could be observed or treated with a shorter duration of adjuvant immunotherapy. In contrast, patients with pPR or pNR on surgical pathology could be treated with a TLND followed by adjuvant immunotherapy with a single-agent PD-1 inhibitor to complete up to one year of treatment. Alternatively, patients with a pNR and <em>BRAF</em>-mutant disease may benefit from TLND and switching to adjuvant targeted therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, since tumors with a pNR are likely resistant to immunotherapy.</p><p class="headingAnchor" id="H970708579"><span class="h4">Neoadjuvant targeted therapy</span><span class="headingEndMark"> — </span>In patients with <em>BRAF</em>-mutant melanoma, the use of neoadjuvant targeted therapy with BRAF plus MEK inhibitors remains investigational. Neoadjuvant targeted therapy results in pCR rates of approximately 50 percent, but durable responses are limited when compared with neoadjuvant immunotherapy [<a href="#rid20">20,27</a>].</p><p>As an example, one meta-analysis evaluated clinical trials of neoadjuvant immunotherapy or targeted therapy in 192 patients with melanoma [<a href="#rid27">27</a>]. In the subset of 51 patients with <em>BRAF</em>-mutant melanoma who received neoadjuvant targeted therapy, a pCR was seen in 24 of 51 patients (47 percent) at median follow-up of 21 months. However, patients who achieved a pCR from targeted therapy were still more likely to relapse at two years than those with any pathologic response to neoadjuvant immunotherapy (21 versus 4 percent). In addition, most patients receiving targeted therapy who did not achieve a pCR relapsed within two years (87 percent).</p><p class="headingAnchor" id="H954592235"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>Other agents are being investigated in the neoadjuvant setting, including <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus relatlimab [<a href="#rid32">32</a>] and <a class="drug drug_general" data-topicid="104964" href="/d/drug information/104964.html" rel="external">talimogene laherparepvec</a> (T-VEC) [<a href="#rid33">33,34</a>].</p><p>The intralesional use of T-VEC to treat unresectable dermal and epidermal melanoma metastases and the use of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus relatlimab for metastatic melanoma are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7608.html" rel="external">"Cutaneous melanoma: In-transit metastases", section on 'Intralesional therapy (T-VEC)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7607.html" rel="external">"Cutaneous melanoma: Management of local recurrence", section on 'Talimogene laherparepvec'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab-relatlimab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Nivolumab-relatlimab'</a>.)</p><p></p><p class="headingAnchor" id="H297426091"><span class="h2">Microscopic disease</span><span class="headingEndMark"> — </span>For patients with high-risk node-positive (AJCC eighth edition stage IIIB, IIIC, and IIID) microscopic disease  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>) who have undergone primary resection and did not receive neoadjuvant therapy prior to surgery, we offer adjuvant systemic therapy, which reduces recurrence risk and improves survival  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>). Microscopic disease is defined as tumor burden detected on sentinel lymph node biopsy. In several phase III trials, adjuvant single-agent immunotherapy improved RFS, and targeted therapy with the BRAF plus MEK inhibitors <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> improved OS in those whose tumors also contained a <em>BRAF</em> mutation. (See <a class="local">'BRAF wild-type tumors'</a> below and <a class="local">'BRAF-mutated tumors'</a> below.)</p><p>Patients with unresectable disease should be evaluated in a multidisciplinary setting to determine appropriate management. Such patients are treated similarly to those with unresectable in-transit or metastatic disease, as indicated, or clinical trials. (See  <a class="medical medical_review" href="/d/html/7608.html" rel="external">"Cutaneous melanoma: In-transit metastases"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p class="headingAnchor" id="H2555192231"><span class="h3">BRAF wild-type tumors</span><span class="headingEndMark"> — </span>For patients with primary resected, high-risk node-positive microscopic disease lacking a <em>BRAF </em>V600 mutation and no prior neoadjuvant therapy, we suggest one year of adjuvant immunotherapy with a PD-1 inhibitor rather than other systemic therapies or surveillance. Options for adjuvant therapy include either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>), as both improved RFS as single agents and were well tolerated. (See <a class="local">'Adjuvant nivolumab'</a> below and <a class="local">'Adjuvant pembrolizumab'</a> below.)</p><p class="headingAnchor" id="H3540376323"><span class="h4">Adjuvant nivolumab</span><span class="headingEndMark"> — </span>In patients with resected high-risk node-positive melanoma, one year of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) improved RFS and reduced toxicity compared with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in a phase III trial [<a href="#rid10">10,35-37</a>].</p><p></p><p>In this study (CheckMate 238), 906 patients with complete resection of AJCC seventh edition stage IIIB, IIIC, or IV melanoma were randomly assigned to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg every two weeks for one year) or <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (10 mg/kg every three weeks for four doses, and then every 12 weeks for up to one year) [<a href="#rid10">10,35,36</a>]. All patients had complete resection of disease within 12 weeks prior to randomization. Approximately 29 percent of patients had microscopic nodal involvement and 71 percent had either macroscopic lymph node disease or resected stage IV disease. The study also enrolled patients with acral and mucosal melanoma but excluded those with ocular melanoma. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment", section on 'Adjuvant immunotherapy'</a>.)</p><p>At a median follow-up of 62 months, the following results were reported [<a href="#rid36">36,37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>All patients</strong> – In the entire study population, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved five-year RFS (50 versus 39 percent, HR 0.72, 95% CI 0.6-0.86). OS was similar between the two treatment arms (five-year OS 76 versus 72 percent, HR 0.86, 95% CI 0.66-1.12).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IIIB to IIIC disease</strong> – In those with stage IIIB and stage IIIC disease, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved five-year RFS (58 versus 48 percent; HR 0.72, 95% CI 0.52-1.01, and 43 versus 35 percent; HR 0.76, 95% CI 0.59-0.97, respectively) and five-year distant metastasis-free survival (DMFS; 58 versus 51 percent, HR 0.79, 95% CI 0.63-0.99). Results for patients with stage IV disease are discussed below. (See <a class="local">'Adjuvant nivolumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong><strong> wild-type tumors</strong> – Among patients with <em>BRAF</em> wild-type disease, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved five-year RFS (47 versus 36 percent; HR 0.69, 95% CI 0.53-0.9). Results for tumors harboring a <em>BRAF</em> mutation are discussed below. (See <a class="local">'Adjuvant nivolumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other subgroups</strong> – A similar degree of improvement in RFS with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was seen in the prespecified major subgroups, including the presence or absence of ulceration, the extent of lymph node involvement (microscopic versus macroscopic), and programmed cell death ligand 1 (PD-L1) expression [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> had fewer grade ≥3 toxicity (14 versus 46 percent) and treatment-related adverse events leading to discontinuation of therapy than <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (4 versus 30 percent) [<a href="#rid10">10</a>]. Late emergent toxicities were similar between the two treatment arms (1 versus 2 percent) [<a href="#rid35">35</a>].</p><p></p><p>Based on these data, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> received regulatory approval from the FDA for adult patients with melanoma and lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting [<a href="#rid38">38</a>]. The use of adjuvant single-agent nivolumab in patients with completely resected metastatic disease and pediatric patients is discussed below. (See <a class="local">'Metastatic disease (stage IV)'</a> below and <a class="local">'Pediatric and adolescent patients'</a> below.)</p><p>The original approval of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> as adjuvant therapy used a schedule of 240 mg every two weeks. Subsequently, an alternative schedule of nivolumab 480 mg every four weeks was approved based upon clinical pharmacology analyses and safety assessments [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3406393158"><span class="h4">Adjuvant pembrolizumab</span><span class="headingEndMark"> — </span>In patients with resected high-risk node-positive melanoma, one year of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) improved RFS and DMFS and reduced toxicity in phase III trials [<a href="#rid39">39-43</a>].</p><p>The efficacy of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) was initially demonstrated in the placebo-controlled phase III KEYNOTE-054 (European Organisation for Research and Treatment of Cancer [EORTC] 1325) trial [<a href="#rid39">39-42</a>]. In that trial, 1019 patients with completely resected stage III disease were randomly assigned to either pembrolizumab (200 mg every three weeks for 18 doses) or placebo.</p><p>At a median follow-up of three years, compared with placebo, data were as follows [<a href="#rid40">40,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – For the entire study population, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved RFS (60 versus 41 percent at 3.5 years, HR 0.59, 95% CI 0.49-0.7) and DMFS (65 versus 49 percent at 3.5 years, HR 0.6, 95% CI 0.49-0.73) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IIIA (at least one lymph node metastasis ≥1 mm), IIIB, and IIIC disease</strong> – <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> improved three-year RFS in patients with stage IIIB and stage IIIC disease (66 versus 47 percent, HR 0.56, 99% CI 0.39-0.81; 54 versus 32 percent, HR 0.57, 99% CI 0.4-0.81, respectively) and trended towards RFS benefit in those with stage IIIA disease, specifically those with ≥1 mm of disease in the lymph nodes (81 versus 66 percent, HR 0.5, 99% CI 0.22-1.16 [<a href="#rid40">40</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong><strong> V600 wild-type tumors</strong> – Among the 449 patients with <em>BRAF </em>V600 wild-type tumors (44 percent), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved three-year RFS (62 versus 47 percent, HR 0.66, 95% CI 0.46-0.95) and trended towards improved DMFS benefit (62 versus 51 percent at 3.5 years, HR 0.73, 95% CI 0.5-1.07) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other subgroups</strong> – A similar degree of improvement in RFS with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was seen in the prespecified major subgroups, including the presence or absence of ulceration and the extent of lymph node involvement (microscopic versus macroscopic) [<a href="#rid40">40</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Serious grade ≥3 adverse events were more common with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> than with placebo (14 versus 3 percent), and there was one treatment-related death due to pembrolizumab (myositis).</p><p></p><p>In a subsequent phase III trial (S1404), one year of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved relapse-free survival and was better tolerated compared with other systemic therapies (high-dose <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) [<a href="#rid43">43,44</a>]. In this study, 1303 patients with high-risk (AJCC seventh edition stage IIIA to IVC) resected melanoma were randomly assigned to adjuvant therapy with either pembrolizumab (200 mg every three weeks for one year); high-dose interferon alfa-2b for one year; or high-dose ipilimumab (10 mg/kg every three weeks for four doses, then every 12 weeks for up to three years).</p><p>At median follow-up of approximately four years, compared with either high-dose <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> or <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved relapse-free survival (HR 0.77, 99.62% CI 0.59-0.99) but not OS (HR 0.82, 96.3% CI 0.61-1.9) in the total study population [<a href="#rid43">43</a>]. It also did not improve OS among those with PD-L1 positive tumors or those with <em>BRAF</em>-mutant disease. Grade ≥3 treatment-related toxicity was less with pembrolizumab (20 percent) compared with ipilimumab (49 percent) and high-dose interferon alfa-2b (72 percent).</p><p>Based on the data from KEYNOTE-054, the FDA granted regulatory approval for adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in patients with resected stage III (lymph node-involved) disease [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1048268713"><span class="h4">Adjuvant therapies not commonly used</span><span class="headingEndMark"> — </span>Other systemic agents have limited roles as adjuvant therapy in patients with resected high-risk node-positive melanoma, due to toxicity, lack of efficacy, and/or the availability of more effective agents. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ipilimumab</strong> – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a>, has regulatory approval as adjuvant therapy in patients with resected node-positive melanoma, but it is not commonly used and has essentially been replaced by other agents. Ipilimumab, which targets cytotoxic T lymphocyte-associated protein 4, is a less ideal adjuvant option due to its toxicity profile. However, if ipilimumab is being considered for adjuvant therapy, we suggest dosing at the 3 mg/kg schedule, which is the same dose used for metastatic disease. Previous data from a randomized phase III trial (EORTC 18071), which led to ipilimumab's approval as adjuvant therapy for melanoma, supported ipilimumab at 10 mg/kg dosing over placebo [<a href="#rid8">8,9,45</a>]. However, this dosing is no longer suggested due to toxicities and subsequent data from the E1609 trial supporting lower doses of ipilimumab.</p><p></p><p class="bulletIndent1">In the phase III E1609 trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02506153%3Fterm%3DNCT02506153%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIkFPEVP7Bb%2FRDOQWmrjfoNsjMcGtZXqSUhKloKe5COU9o%3D&amp;TOPIC_ID=7615" target="_blank">"NCT01274338"</a>), 1670 patients with resected melanoma were randomly assigned to either <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> at 10 or 3 mg/kg dosing or to high-dose <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> [<a href="#rid46">46</a>]. After a median follow-up of 58 months, ipilimumab at the 3 mg/kg dose, in comparison with high-dose interferon alfa-2b, demonstrated improved OS (five-year OS 72 versus 67 percent, HR 0.78, 95% CI 0.61-0.99) and similar RFS. However, ipilimumab at the 10 mg/kg dose did not demonstrate a difference in OS or RFS when compared with interferon alfa-2b, possibly because over 50 percent of patients discontinued therapy due to toxicity. Rates of grade ≥3 toxicities were 37 percent with ipilimumab 3 mg/kg and 58 percent with ipilimumab 10 mg/kg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon alfa-2b</strong> – <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">Interferon alfa-2b</a> no longer has a well-defined role in the adjuvant setting for cutaneous melanoma. Prior to the development of checkpoint inhibitor immunotherapy, high-dose interferon alfa-2b was the only option for adjuvant treatment of high-risk melanoma that improved OS. The use of high-dose interferon alfa-2b was supported by the results of the Eastern Cooperative Oncology Group 1684 and Intergroup E1694 trials, as well as a meta-analysis that included results from trials with various schedules and doses [<a href="#rid47">47-50</a>]. However, this agent is associated with numerous serious side effects, such as acute constitutional symptoms, chronic fatigue, myelosuppression, hepatotoxicity, as well as neurological and psychological effects [<a href="#rid51">51</a>]. Interferon alfa-2b also has limited availability, as the manufacturer has discontinued production.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong> – We do not offer the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> as adjuvant therapy in patients with non-metastatic, resected, high-risk node-positive disease. In a randomized phase III trial (CheckMate 915), adjuvant nivolumab plus ipilimumab did not improve relapse-free survival over adjuvant nivolumab monotherapy in patients with advanced resected stage IIIB-D or IV melanoma [<a href="#rid52">52,53</a>]. Single-agent nivolumab remains one preferred option for adjuvant therapy in this population. (See <a class="local">'Adjuvant nivolumab'</a> above.)</p><p></p><p class="bulletIndent1">The use of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> for resected metastatic (stage IV) melanoma is discussed below. (See <a class="local">'Adjuvant nivolumab plus ipilimumab'</a> below.)</p><p></p><p class="headingAnchor" id="H546034859"><span class="h3">BRAF-mutated tumors</span></p><p class="headingAnchor" id="H1752231954"><span class="h4">Choice of therapy</span><span class="headingEndMark"> — </span>For patients with primary resected, high-risk node-positive microscopic disease with a <em>BRAF</em> V600 driver mutation and no prior neoadjuvant therapy, options for adjuvant therapy include <strong>either </strong>one year of immunotherapy with either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>), <strong>or</strong> one year of targeted therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>. In these patients, immunotherapy and targeted therapy are both effective options with different toxicity profiles. However, the optimal adjuvant therapy has not been established, since these agents have not been directly compared in randomized trials. (See <a class="local">'Factors that influence therapy'</a> above.)</p><p>Patient characteristics and preferences can be used to guide selection of therapy. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant immunotherapy can be offered to patients who are willing to accept the potential long-term toxicities, primarily endocrine, for a chance at achieving durable treatment-free survival. Durable treatment-free survival is a hallmark of immunotherapy in the management of patients with distant metastatic disease, but less commonly seen with BRAF plus MEK inhibitors in that setting. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Previously untreated patients'</a> and  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1">However, adjuvant <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> is also an appropriate option in these patients, as it improved OS in a phase III trial [<a href="#rid11">11</a>]. Additionally, while toxicities from targeted therapy are common and can affect multiple organ systems, they are typically manageable and/or reversible once treatment is discontinued. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> is an alternative for patients who cannot receive immunotherapy (eg, due to immunosuppressive therapy or corticosteroids); those at greater risk for immune-related adverse events (irAEs); and/or those who prefer the convenience of oral targeted therapy over intravenous treatment with immunotherapy, after a thorough risk-benefit discussion with the treating clinician. (See <a class="local">'Adjuvant dabrafenib plus trametinib'</a> below.)</p><p></p><p class="headingAnchor" id="H2435014027"><span class="h4">Adjuvant nivolumab</span><span class="headingEndMark"> — </span>One year of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) is an option for patients with high-risk node-positive disease and a <em>BRAF</em> V600 mutation who are eligible to receive immunotherapy.</p><p>In a phase III trial (CheckMate 238), one year of adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved RFS over <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> among 906 patients with complete resection of AJCC seventh edition stage IIIB, IIIC, or IV melanoma [<a href="#rid10">10,35-37</a>]. Among the subset of 381 patients with <em>BRAF</em> mutant tumors, nivolumab trended towards improved five-year RFS compared with ipilimumab (50 versus 42 percent; HR 0.8, 95% CI 0.6-1.05) [<a href="#rid36">36</a>]. Results for the entire study population are discussed above. (See <a class="local">'Adjuvant nivolumab'</a> above.)</p><p class="headingAnchor" id="H3399233317"><span class="h4">Adjuvant pembrolizumab</span><span class="headingEndMark"> — </span>One year of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) is an option for patients with high-risk node-positive disease and a <em>BRAF</em> V600 mutation who are eligible to receive immunotherapy.</p><p>A placebo-controlled phase III trial (KEYNOTE-054) [<a href="#rid39">39-42</a>] of 1019 patients with completely resected stage III (including stage IIIA tumors with ≥1 mm of disease in the lymph nodes) melanoma also included a subset of 440 patients with <em>BRAF</em> V600 mutated tumors. In this subgroup, at median follow-up of three years, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved three-year RFS (62 versus 37 percent, HR 0.51, 99% CI 0.36-0.73) and DMFS (64 versus 44 percent at 3.5 years, HR 0.53, 95% CI 0.36-0.77) [<a href="#rid39">39,40</a>]. Results for the entire study population are discussed above. (See <a class="local">'Adjuvant pembrolizumab'</a> above.)</p><p class="headingAnchor" id="H2953346561"><span class="h4">Adjuvant dabrafenib plus trametinib</span><span class="headingEndMark"> — </span>One year of adjuvant therapy with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> is a reasonable alternative to immunotherapy for select patients with high-risk node-positive disease whose tumor contains a <em>BRAF</em> V600 mutation. For example, targeted therapy may be offered to those at greater risk for irAEs (eg, due to medical comorbidities, and/or active autoimmune disease) or those who cannot receive immunotherapy due to immunosuppressive therapy or corticosteroid use. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Defining immunotherapy eligibility'</a>.)</p><p><a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">Dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> is also acceptable adjuvant therapy for those with a <em>BRAF</em> V600 mutation at lower risk for disease recurrence (stage IIIA). (See <a class="local">'Low-risk node-positive disease (stage IIIA)'</a> above.)</p><p><a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">Dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> improved RFS and OS in the adjuvant setting [<a href="#rid11">11,54-56</a>]. Based on initial phase III data confirming the efficacy of adjuvant <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, a single-agent BRAF inhibitor [<a href="#rid57">57</a>], the combination of dabrafenib plus trametinib was evaluated in a phase III trial (COMBI-AD). In this study, 870 patients with completely resected <em>BRAF</em> V600 mutation-positive stage III melanoma were randomly assigned to the combination of dabrafenib (150 mg twice a day) plus trametinib (2 mg once a day) or to matching placebos for one year [<a href="#rid11">11,54-56</a>].</p><p>At a median follow-up of five years, compared with placebo, the combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> improved both five-year RFS (52 versus 36 percent; HR 0.51, 95% CI 0.42-0.61) and DMFS at five years (65 versus 54 percent, HR 0.55, 95% CI 0.44-0.7) [<a href="#rid56">56</a>]. The combination also improved OS at three years (86 versus 77 percent; HR 0.57, 95% CI 0.42-0.79) [<a href="#rid11">11</a>]. Treatment benefit for the combination was observed irrespective of baseline factors, according to subgroup analysis [<a href="#rid54">54</a>].</p><p>Based upon this trial, the combination of <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> was approved by the FDA for adjuvant use for patients with lymph node involvement and a <em>BRAF</em> V600E or V600K mutation [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H1901019738"><span class="h1">METASTATIC DISEASE (STAGE IV)</span></p><p class="headingAnchor" id="H3800468255"><span class="h2">Adjuvant nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with stage IV disease, regardless of <em>BRAF </em>V600<em> </em>mutation<em> </em>status, who have undergone primary definitive treatment of all sites of disease with either surgery or radiation therapy, we suggest adjuvant immunotherapy with the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (1 mg/kg every three weeks) plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (3 mg/kg every three weeks) for four doses, followed by maintenance nivolumab to complete a year of therapy, rather than surveillance alone, as this approach improved overall survival (OS) in a randomized trial [<a href="#rid60">60,61</a>].</p><p>Some UpToDate experts also offer an alternative dosing strategy for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (ie, nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg every three weeks for four doses), based on results of a randomized trial comparing dosing strategies in patients with measurable metastatic disease. This study, although underpowered, demonstrated similar efficacy for both regimens and reduced toxicity for the alternative regimen [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p>Adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improved recurrence-free survival (RFS) and OS in a double-blind, placebo-controlled phase II trial (IMMUNED). In this study, 167 patients with stage IV melanoma with no evidence of disease after treatment with surgery or radiation therapy were randomly assigned to adjuvant immunotherapy with either four cycles of nivolumab plus ipilimumab followed maintenance nivolumab monotherapy, nivolumab monotherapy, or placebo [<a href="#rid60">60,61</a>]. In all treatment arms, maintenance therapy was continued up to one year, unacceptable toxicity, or disease recurrence.</p><p>At median follow-up of 49 months, results for the entire study population were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improved RFS compared with placebo (four-year RFS 64 versus 15 percent, hazard ratio [HR] 0.25, 97.5% CI 0.13-0.48) and nivolumab monotherapy (four-year RFS 64 versus 31 percent, HR 0.41, 97.5% CI 0.22-0.78) [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> also improved OS compared with placebo (four-year OS 84 versus 63 percent, HR 0.41, 97.5% CI 0.17-0.99) but not nivolumab (four-year OS 84 versus 73 percent, HR 0.55, 97.5% CI 0.22-1.38).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> monotherapy also improved RFS but failed to improve OS compared with placebo (four-year RFS 31 versus 15 percent, HR 0.6, 97.5% CI 0.36-1.00; four-year OS 73 versus 63 percent, HR 0.75, 97.5% 0.36-1.56).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade ≥3 toxicities were higher for combination immunotherapy versus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone (71 versus 29 percent).</p><p></p><p>Among those with a <em>BRAF </em>V600 mutation, the combination also improved RFS compared with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> monotherapy (HR 0.25, 95% CI 0.09-0.69) and placebo (HR 0.11, 95% CI 0.04-0.29).</p><p>A separate phase III trial (CheckMate 915) which also evaluated <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in a subset of patients with stage IV disease did not show an RFS benefit over single agent nivolumab. However, this trial used an alternative dosing for the combination (nivolumab 240 mg every two weeks and ipilimumab 1 mg/kg every six weeks) whereas the IMMUNED trial used standard dosing. (See <a class="local">'Adjuvant therapies not commonly used'</a> above.)</p><p>The use of combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in those with unresectable metastatic (stage IV) disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p class="headingAnchor" id="H3680138237"><span class="h2">Adjuvant nivolumab</span><span class="headingEndMark"> — </span>For those who are unable to tolerate the potential toxicities of combination <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we alternatively offer adjuvant nivolumab monotherapy for one year  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>). Although nivolumab has not been shown to improve OS, it has a more manageable toxicity profile and has regulatory approval as adjuvant therapy in patients with completely resected stage IV disease. (See <a class="local">'Adjuvant nivolumab'</a> above.)</p><p>A randomized phase III trial (CheckMate 238) of patients with high-risk resected melanoma included a subset of 169 patients with stage IV disease [<a href="#rid35">35-37</a>]. Among this subset of patients, adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> trended towards higher five-year RFS over <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, although the results were not statistically significant. Patients with M1a or M1b disease had a five-year RFS of 47 versus 29 percent (HR 0.64, 95% CI 0.40-1.01) while patients with M1c disease had a five-year RFS of 55 versus 49 percent (HR 0.98, 95% CI 0.39-2.47).</p><p>Similarly, in a randomized trial (IMMUNED) of patients with definitively treated stage IV melanoma, adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> monotherapy improved RFS versus placebo but failed to improve OS versus adjuvant nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid61">61</a>]. These data are discussed above. (See <a class="local">'Adjuvant nivolumab plus ipilimumab'</a> above.)</p><p class="headingAnchor" id="H3902155726"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1597747974"><span class="h2">Pediatric and adolescent patients</span><span class="headingEndMark"> — </span>Adjuvant therapy is offered to pediatric and adolescent patients with localized melanoma at increased risk for disease recurrence, extrapolating from the same treatment approach used in adults. (See <a class="local">'Factors that influence therapy'</a> above.)</p><p class="headingAnchor" id="H1735044588"><span class="h3">Adjuvant pembrolizumab</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved by the US Food and Drug Administration (FDA) for the adjuvant treatment of pediatric patients (12 years and older) with stage IIB, IIC, or III melanoma following complete resection [<a href="#rid12">12</a>]. Pediatric dosing for adjuvant pembrolizumab is available at 2 mg/kg (up to a maximum of 200 mg) every three weeks for up to 12 months  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>). </p><p>Data are limited for the efficacy of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in children and adolescents. As an example, one phase III trial (KEYNOTE-716) evaluated the use of adjuvant pembrolizumab in patients with high-risk node-negative disease [<a href="#rid5">5</a>]. This trial only enrolled two pediatric patients (children between the ages of 12 and 17 years), who were treated with a pediatric dosing of pembrolizumab. Results of this trial for the entire study population are discussed above. (See <a class="local">'Adjuvant pembrolizumab'</a> above.)</p><p class="headingAnchor" id="H1178080584"><span class="h3">Adjuvant nivolumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) is approved by the FDA for the adjuvant treatment of pediatric patients (12 years and older) with stage IIB to IV melanoma who have undergone complete resection [<a href="#rid14">14</a>]. This approach is extrapolated from clinical trials of adjuvant nivolumab in adults with melanoma (CheckMate-238) [<a href="#rid10">10</a>]. Additional pharmacokinetic studies in pediatric patients also demonstrate similar exposure to nivolumab as that reported in adults [<a href="#rid63">63</a>]. (See <a class="local">'Adjuvant nivolumab'</a> above.)</p><p class="headingAnchor" id="H1258867528"><span class="h1">RECURRENCE AFTER ADJUVANT THERAPY</span><span class="headingEndMark"> — </span>For patients who recur with metastatic disease after initial adjuvant therapy, the approach to therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Prior adjuvant systemic therapy'</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Prior treatment with single-agent PD-1 inhibitors (including adjuvant therapy)'</a>.)</p><p class="headingAnchor" id="H191201076"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that influence therapy</strong> – For patients with resectable cutaneous melanoma, the choice of adjuvant or neoadjuvant therapy is influenced by risk of disease recurrence (based upon thickness and ulceration of the primary tumor and/or the presence of lymph node metastases), tumor stage, and <em>BRAF</em> mutation status  (<a class="graphic graphic_algorithm graphicRef135087" href="/d/graphic/135087.html" rel="external">algorithm 1</a>). (See <a class="local">'Factors that influence therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk node-negative disease</strong> – For patients with low-risk node-negative (American Joint Committee on Cancer [AJCC] eighth edition stage I or IIA  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) disease, we perform surveillance alone after surgery without adjuvant therapy. Since these patients are at low risk for disease recurrence, surgery alone is usually curative. (See <a class="local">'Low-risk node-negative disease (stage I and IIA)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk node-negative disease</strong> – For patients with high-risk node-negative (stage IIB and IIC  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) disease, we suggest one year of adjuvant immunotherapy with either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) rather than surveillance (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). However, surveillance or enrollment in a clinical trial are reasonable alternatives, particularly for those with stage IIB disease given their likely lower recurrence risk. (See <a class="local">'High-risk node-negative disease (stage IIB and IIC)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk node-positive disease</strong> – For patients with low-risk node-positive (stage IIIA  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) disease, our approach is as follows (see <a class="local">'Low-risk node-positive disease (stage IIIA)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with resected stage IIIA disease who have a non-ulcerated tumor ≤2 mm in thickness and sentinel lymph nodes containing &lt;1 mm of tumor, we suggest surveillance rather than systemic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), as these patients have a lower risk of disease recurrence (estimated at less than 20 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all other patients with resected stage IIIA melanoma, we treat with one year of adjuvant systemic therapy. The choice of therapy is based upon the <em>BRAF</em> mutation status of the tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk node-positive disease </strong>– For patients with high-risk node-positive (AJCC eighth edition stage IIIB, IIIC, and IIID  (<a class="graphic graphic_table graphicRef110663 graphicRef110664" href="/d/graphic/110663.html" rel="external">table 1A-B</a>)) melanoma, our treatment approach is as follows (see <a class="local">'High-risk node-positive disease (stage IIIB, IIIC, IIID)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Macroscopic disease</strong> – For patients with macroscopic disease that is resectable, we suggest initial treatment with neoadjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than primary surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), based on improved event-free survival (EFS) in a randomized trial. Macroscopic disease is defined as clinically detected lymph nodes on radiographic imaging or physical exam, or visible in-transit or satellite metastases that are subsequently confirmed on pathology (eg, fine needle aspiration [FNA] or excisional biopsy). (See <a class="local">'Macroscopic disease'</a> above and <a class="local">'Neoadjuvant pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent2">Alternative options for neoadjuvant therapy include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or enrollment in clinical trials investigating other neoadjuvant regimens. (See <a class="local">'Neoadjuvant nivolumab plus ipilimumab'</a> above and <a class="local">'Investigational approaches'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microscopic disease</strong> – For patients with primary resected microscopic disease and no prior neoadjuvant therapy, options for adjuvant systemic therapy include immunotherapy or targeted therapy for <em>BRAF</em> V600 mutated tumors. Microscopic disease is defined as tumor burden detected on sentinel lymph node biopsy. (See <a class="local">'Microscopic disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>BRAF</em></strong><strong> wild-type tumors</strong> – For tumors lacking a <em>BRAF </em>V600 mutation, we suggest one year of adjuvant immunotherapy with a programmed cell death-1 (PD-1) inhibitor rather than other systemic therapies or surveillance (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), as this approach improves RFS and is well tolerated. Options for adjuvant therapy include either single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>). (See <a class="local">'BRAF wild-type tumors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>BRAF</em></strong><strong>-mutated tumors</strong> – For tumors with a <em>BRAF </em>V600 driver mutation, options include <strong>either </strong>one year of adjuvant immunotherapy with either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef134308" href="/d/graphic/134308.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef131202" href="/d/graphic/131202.html" rel="external">table 2</a>) <strong>or </strong>one year of targeted therapy with a combination of the BRAF plus MEK inhibitors <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>. Both are effective options with different toxicity profiles, and patient characteristics and preferences are used to guide selection of therapy. (See <a class="local">'BRAF-mutated tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic disease</strong> – For patients with metastatic (stage IV) disease, regardless of <em>BRAF</em> V600<em> </em>mutation<em> </em>status, who have undergone primary definitive treatment of all sites of metastatic disease, we suggest adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> followed by maintenance nivolumab, rather than surveillance alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), which improved overall survival (OS). (See <a class="local">'Metastatic disease (stage IV)'</a> above.)</p><p></p><p class="bulletIndent1">While adjuvant <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone is an acceptable alternative for those who are unable to tolerate the potential toxicities of combination immunotherapy, it has not been shown to improve OS. (See <a class="local">'Adjuvant nivolumab'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.</a></li><li class="breakAll">Melanoma of the skin. In: American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, 2010. p.325.</li><li><a class="nounderline abstract_t">Haydu LE, Lo SN, McQuade JL, et al. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 2020; 38:1429.</a></li><li><a class="nounderline abstract_t">Sullivan RJ, Atkins MB, Kirkwood JM, et al. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer 2018; 6:44.</a></li><li><a class="nounderline abstract_t">Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022; 399:1718.</a></li><li><a class="nounderline abstract_t">Khattak MA, Luke JJ, Long GV, et al. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer 2022; 176:207.</a></li><li><a class="nounderline abstract_t">Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2022; 23:1378.</a></li><li><a class="nounderline abstract_t">Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522.</a></li><li><a class="nounderline abstract_t">Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer 2019; 119:1.</a></li><li><a class="nounderline abstract_t">Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377:1824.</a></li><li><a class="nounderline abstract_t">Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377:1813.</a></li><li class="breakAll">Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf (Accessed on April 12, 2023).</li><li class="breakAll">Long et al. Adjuvant therapy with nivolumab versus placebo in patients with Stage IIB/C melanoma (CheckMate-76K). Society of Melanoma Research. Presented as a late-breaking plenary abstract on October 19, 2022. https://clin.larvol.com/abstract-detail/SMR%202022/60490438 (Accessed on December 06, 2022).</li><li class="breakAll">OPDIVO (nivolumab) injection, for intravenous use. United States Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554Orig1s121lbl.pdf (Accessed on October 20, 2023).</li><li><a class="nounderline abstract_t">Madu MF, Franke V, Van de Wiel BA, et al. External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment? Melanoma Res 2020; 30:185.</a></li><li><a class="nounderline abstract_t">Garbe C, Keim U, Suciu S, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol 2020; 38:2543.</a></li><li><a class="nounderline abstract_t">Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472.</a></li><li><a class="nounderline abstract_t">Moncrieff MD, Lo SN, Scolyer RA, et al. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol 2022; 40:3940.</a></li><li><a class="nounderline abstract_t">Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023; 388:813.</a></li><li><a class="nounderline abstract_t">Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019; 20:e378.</a></li><li><a class="nounderline abstract_t">Long GV, Carlino MS, Au-Yeung G, et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. J Clin Oncol 2022; 40;16S.</a></li><li><a class="nounderline abstract_t">Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018; 24:1649.</a></li><li><a class="nounderline abstract_t">Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019; 25:454.</a></li><li><a class="nounderline abstract_t">Kendra KL, Moon J, Eroglu Z, et al. Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). J Clin Oncol 2022; 40;16S.</a></li><li><a class="nounderline abstract_t">Sharon CE, Tortorello GN, Ma KL, et al. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol 2023; 34:806.</a></li><li><a class="nounderline abstract_t">Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019; 20:948.</a></li><li><a class="nounderline abstract_t">Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021; 27:301.</a></li><li><a class="nounderline abstract_t">Versluis JM, Reijers ILM, Rozeman EA, et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer 2021; 148:51.</a></li><li><a class="nounderline abstract_t">Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surg 2022; 157:335.</a></li><li><a class="nounderline abstract_t">Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022; 28:1178.</a></li><li><a class="nounderline abstract_t">Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023; 34:420.</a></li><li><a class="nounderline abstract_t">Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 2022; 611:155.</a></li><li><a class="nounderline abstract_t">Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med 2021; 27:1789.</a></li><li><a class="nounderline abstract_t">Dummer R, Gyorki DE, Hyngstrom JR, et al. Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. JAMA Oncol 2023; 9:1457.</a></li><li><a class="nounderline abstract_t">Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21:1465.</a></li><li class="breakAll">Weber J, Larkin J, Mandala M, et al. Five-year outcomes with adjuvant nivolumab versus ipilimumab in resected stage IIIB–C or IV melanoma (CheckMate 238). Presented at the Society for Melanoma Research October 28-21, 2021.</li><li><a class="nounderline abstract_t">Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res 2023; 29:3352.</a></li><li class="breakAll">Nivolumab: US Food and Drug Administration (FDA) Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf (Accessed on February 20, 2023).</li><li><a class="nounderline abstract_t">Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378:1789.</a></li><li><a class="nounderline abstract_t">Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol 2020; 38:3925.</a></li><li><a class="nounderline abstract_t">Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22:643.</a></li><li><a class="nounderline abstract_t">Bottomley A, Coens C, Mierzynska J, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22:655.</a></li><li><a class="nounderline abstract_t">Grossmann KF, Othus M, Patel SP, et al. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov 2022; 12:644.</a></li><li><a class="nounderline abstract_t">Unger JM, Darke A, Othus M, et al. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol 2023; 9:251.</a></li><li><a class="nounderline abstract_t">Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375:1845.</a></li><li><a class="nounderline abstract_t">Tarhini AA, Lee SJ, Hodi FS, et al. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol 2020; 38:567.</a></li><li><a class="nounderline abstract_t">Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7.</a></li><li><a class="nounderline abstract_t">Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370.</a></li><li><a class="nounderline abstract_t">Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493.</a></li><li><a class="nounderline abstract_t">Najjar YG, Puligandla M, Lee SJ, Kirkwood JM. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer 2019; 125:3013.</a></li><li><a class="nounderline abstract_t">Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112:982.</a></li><li><a class="nounderline abstract_t">Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). J Clin Oncol 2023; 41:517.</a></li><li><a class="nounderline abstract_t">Long G, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB–D/IV melanoma (CheckMate 915) In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15. Philadelphia (PA): AACR; 2021. Abstract. Cancer Res 2021.</a></li><li><a class="nounderline abstract_t">Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018; 36:3441.</a></li><li><a class="nounderline abstract_t">Dummer R, Brase JC, Garrett J, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 2020; 21:358.</a></li><li><a class="nounderline abstract_t">Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020; 383:1139.</a></li><li><a class="nounderline abstract_t">Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018; 19:510.</a></li><li class="breakAll">US Food and Drug Administration (FDA) label for dabrafenib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf?et_cid=40266296&amp;et_rid=931310737&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f202806s008lbl.pdf (Accessed on June 08, 2020).</li><li class="breakAll">US Food and Drug Administration (FDA) label for trametinib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s007lbl.pdf?et_cid=40266296&amp;et_rid=931310737&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f204114s007lbl.pdf (Accessed on June 08, 2020).</li><li><a class="nounderline abstract_t">Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 395:1558.</a></li><li><a class="nounderline abstract_t">Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet 2022; 400:1117.</a></li><li><a class="nounderline abstract_t">Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol 2019; 37:867.</a></li><li><a class="nounderline abstract_t">Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:541.</a></li></ol></div><div id="topicVersionRevision">Topic 7615 Version 123.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917835" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Final version of 2009 AJCC melanoma staging and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917835" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Final version of 2009 AJCC melanoma staging and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990608" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29848375" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35367007" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36202690" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36265502" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840693" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400634" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891423" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891408" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891408" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891408" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31651715" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32530760" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028110" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35849790" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36856617" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31267972" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297909" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30804515" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37414215" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558722" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735809" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35138335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661157" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36681299" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36289334" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neoadjuvant relatlimab and nivolumab in resectable melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34608333" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37561473" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32961119" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32961119" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37058595" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37058595" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29658430" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32946353" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857412" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857414" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34764195" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36416836" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27717298" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31880964" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558223" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11331315" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179267" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31067358" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236459" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36162037" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB–D/IV melanoma (CheckMate 915) In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15. Philadelphia (PA): AACR; 2021. Abstract</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343620" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007138" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877599" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477665" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477665" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477665" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416781" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36099927" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811280" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192573" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
